UK markets closed

Bausch Health Companies Inc. (BHC)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
29.25+0.18 (+0.62%)
At close: 4:00PM EDT

29.30 +0.05 (0.17%)
After hours: 5:44PM EDT

Bausch Health Companies Inc.

2150 St. ElzEar Boulevard West
Laval, QC H7L 4A8
514 744 6792

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees21,600

Key executives

NameTitlePayExercisedYear born
Mr. Joseph C. PapaCEO & Chairman3.74MN/A1956
Mr. Paul S. HerendeenExec. VP & CFO2.1MN/A1956
Ms. Christina M. AckermannExec. VP, Gen. Counsel & Head of Commercial Operations1.31MN/A1965
Mr. Thomas J. AppioPres & Co-Head Bausch + Lomb/International2.16MN/A1962
Mr. Osama A. EldessoukySr. VP, Controller & Chief Accounting OfficerN/AN/A1972
Dr. Robert F. ButzVP of Medical & Scientific AffairsN/AN/AN/A
Mr. Arthur J. ShannonSr. VP and Head of Investor Relations & Global CommunicationsN/AN/AN/A
Mr. Michael McMyneVP of SalesN/AN/AN/A
Ms. Stacey WilliamsVP of MarketingN/AN/AN/A
Ms. Kelly WebberSr. VP & Chief HR OfficerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Salix segment provides gastroenterology products in the United States. The Ortho Dermatologics segment offers dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment provides pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Corporate governance

Bausch Health Companies Inc.’s ISS governance QualityScore as of 30 April 2021 is 2. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 4; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.